NEW YORK (AP) -- A Cowen & Co. analyst downgraded shares of Baxter International on Wednesday, saying its hemophilia drug Advate faces a greater threat than he had realized. THE OPINION: Analyst ...

A post-hoc analysis has identified an interrelation between peak levels of factor VIII (:FVIII) in a patient’s body in the first few hours after infusion and the efficiency of prophylaxis treatment in ...

A meta-analysis of post-authorization safety studies (:PASS) of the Advate demonstrated that the product lowers inhibitor rate and is safe and effective for use in routine clinical practices. The ...

Baxter International Inc. said Thursday that it will pull back some promotional literature for its new blood-clotting drug after a warning from the U.S. Food and Drug Administration. The ...

Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...

SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT (TM) FOR ADVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A First and only FDA-cleared PK dosing software to support ...

Baxter announced that the FDA has approved Advate (antihemophilic Factor VIII [recombinant]) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with ...

Shire plc recently launched ADVATE (Octocog alfa – Recombinant Coagulation Factor VIII) in India for the treatment and prophylaxis of bleeding in patients with haemophilia A ADVATE, which came to ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis ...

ADVATE (antihemophilic factor [recombinant] plasma/albumin-free method) 4000IU for IV use by Baxter Baxter announced that the FDA has approved a new 4000 IU dosage strength of Advate (Antihemophilic ...

Hemophilia patients in Indianow have more treatment options as global biotechnology major Shire announced that doctors in India can now prescribe ADVATE, a widely used treatment for Hemophilia A.

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis ...